COR vs NBIX · P/E 21, rev $321.33B vs P/E 45, rev $2.36B
Cencora Inc. (COR) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Cencora Inc. (COR) is a medical distribution company listed on NYSE.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported COR revenue for 2025-09-30 was $321.33B. Net income was $1.57B. Revenue was up 9.3% from 2024-09-30 to 2025-09-30. COR currently screens at market cap $53.91B and trailing P/E 21.2.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
COR currently screens at market cap $53.91B and trailing P/E 21.2. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the COR and NBIX stock pages for the full models.
Not investment advice.